Clinical Trials : Idiopathic Thrombocytopenic Purpura


Completed	: Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP) : Idiopathic Thrombocytopenic Purpura (ITP) : 2012-10-18 : Drug: rituximab infusion of 4 weekly doses of 375 mg/m2 rituximab
Completed	: Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim : Idiopathic Thrombocytopenic Purpura : 2010-06-10 : Biological: Romiplostim Romiplostim will be administered weekly by subcutaneous injection
Recruiting	: Long-term Safety Study of Treatment With the Thrombopoietin Agonists Eltrombopag and Romiplostim in Patients With Immune Thrombocytopenia (ITP) : Idiopathic Thrombocytopenic Purpura : 2011-09-13
Completed	: Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003 : Idiopathic Thrombocytopenic Purpura : 2008-02-19 : Drug: Blinded (placebo)
Completed	: Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP) : Chronic Idiopathic Thrombocytopenic Purpura Purpura, Thrombocyt : 2007-10-05 : Drug: SB-497115-GR 12.5mg SB-4
RECRUITING	: Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITP : Idiopathic Thrombocytopenic Purpura : 2024-11-21 : Once a week as a subcutaneous injection.The initial dose is 1 mcg/kg.